The FDA cleared the first cholesterol pill that works like the injections doctors have pushed for years

For years, the most powerful cholesterol-lowering drugs after statins have come with a catch: patients had to inject them. Now that class has a pill. Federal regulators have approved the first oral version of a PCSK9 inhibitor, the type of medicine that can slash so-called bad cholesterol by more than half but until now was available only as a shot given every few weeks. The decision gives clinicians a new tool for adults whose cholesterol stays high despite existing treatment, and it removes the needle from a therapy many patients had resisted for that reason alone.

The approval covers a drug called Lipfendra, known generically as enlicitide, cleared as an addition to diet and exercise for adults with high cholesterol. It arrives at a moment when heart disease remains the leading cause of death nationwide and elevated cholesterol is one of the most treatable contributors to that toll.

How PCSK9 inhibitors lower LDL cholesterol

PCSK9 is a protein that regulates how efficiently the liver clears low-density lipoprotein, or LDL, from the bloodstream. When PCSK9 is active, it degrades the receptors that pull LDL out of circulation, so more of the cholesterol stays in the blood. Blocking that protein lets the liver keep more receptors on duty and drives LDL levels down sharply. According to the Food and Drug Administration’s announcement of the approval, the agency cleared Lipfendra for adults with hypercholesterolemia, including people with an inherited form called heterozygous familial hypercholesterolemia. The regulator described the new tablet as a once-daily oral option for patients who need further LDL reduction despite the therapies already available to them.

The clinical stakes are well understood. Excess LDL builds up inside artery walls over time, forming plaques that narrow blood vessels; if a plaque ruptures, it can trigger a clot that causes a heart attack or stroke. Because high cholesterol usually produces no symptoms, many people do not know they have it until a blood test or a cardiac event reveals the problem.

What the enlicitide trials showed

The clearance rested on two randomized, double-blind, placebo-controlled studies that together enrolled 3,207 adults already taking the highest dose of statin they could tolerate. Both trials measured the percentage change in LDL cholesterol from the start of treatment to week 24, compared with a placebo. The first study focused on adults who either had established atherosclerotic cardiovascular disease or were at high risk for it; those participants began with a mean LDL level of 96 milligrams per deciliter, and adding the drug produced an average 56 percent reduction by week 24. The second study enrolled adults with the inherited form of high cholesterol, who started higher at a mean of 119 milligrams per deciliter, and there the drug delivered an average 59 percent reduction.

Those figures put the oral drug in the same territory as the injectable PCSK9 inhibitors that cardiologists have prescribed for years, which is the crux of why the approval matters. On tolerability, regulators reported that adverse reactions in the first trial occurred at rates similar to placebo, while in the second trial the most common side effects seen more often with the drug than with placebo were diarrhea and dizziness. Rates of patients stopping treatment because of side effects were comparable between the drug and placebo groups across both studies.

From injections to a once-daily tablet

Several classes of medicine already exist to lower LDL, including statins, ezetimibe, and the injectable PCSK9 inhibitors. What sets the new approval apart is the route of delivery. An oral tablet is far easier to incorporate into a daily routine than a periodic self-injection, and for some patients the difference is decisive. The chemistry behind the pill is notable in its own right: enlicitide is a macrocyclic peptide engineered to survive digestion and still bind PCSK9, blocking its interaction with the LDL receptor much as the antibody injections do. Peptides are notoriously difficult to formulate as pills because the gut tends to break them down, so producing an orally active PCSK9 blocker represents a genuine pharmaceutical advance rather than a simple reformulation.

Convenience is not a trivial concern in cardiology. Patients who stop refilling injections, or who never start them because of a fear of needles, lose the protection the drug is meant to provide. A tablet that matches the injections on LDL lowering could widen the pool of people willing to use this class of medicine at all, though prescribers will still weigh cost, insurance coverage, and each patient’s overall risk before switching.

Priority Review and the regulatory path

The application moved through the agency on an expedited track. Regulators granted the drug Priority Review, a designation reserved for treatments that would offer a significant improvement over available options, and also routed it through a newer pilot meant to speed the evaluation of therapies addressing national public health priorities. The approval was granted to Merck Sharp & Dohme, and in announcing it the agency framed the decision within a broader push to confront chronic cardiovascular disease.

The public-health rationale is straightforward. Federal health data have long identified heart disease as the leading cause of death in the United States, and elevated LDL cholesterol ranks among its most important modifiable risk factors. A statement from the drug’s maker accompanying the launch described Lipfendra as the first and only once-daily oral PCSK9 inhibitor cleared in the country, positioning it as a maintenance therapy for people who need deeper cholesterol reduction than statins alone can deliver. Whether the pill reshapes prescribing habits will depend on real-world use, but the approval closes a long-standing gap between what the strongest cholesterol drugs can do and how easily patients can take them.

This article was produced with AI assistance and reviewed by Morning Overview editors.

More from Morning Overview